Stueland Katherine's Form 4 filing
GeneDx Holdings Corp. (WGS) · filed Mar 30, 2026
- Accession no.
- 0001689575-26-000021
- Filed
- Mar 30, 2026
- Trade date
- Mar 26, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.96M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Stueland KatherineCIK 0001689575 | Director, Officer (CHIEF EXECUTIVE OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | Class A Common Stock | MOption exerciseAcquired | +80,000 | $0.00F1 | $0 | 138,447 | Direct | |
| Mar 26, 2026 | Class A Common Stock | SSaleDisposed | −13,229 | $61.29F3 | −$810,805.41 | 125,218 | Direct | |
| Mar 26, 2026 | Class A Common Stock | SSaleDisposed | −5,117 | $62.33F4 | −$318,942.61 | 120,101 | Direct | |
| Mar 26, 2026 | Class A Common Stock | SSaleDisposed | −13,412 | $63.28F5 | −$848,711.36 | 106,689 | Direct | |
| Mar 26, 2026 | Class A Common Stock | SSaleDisposed | −5,292 | $64.60F6 | −$341,863.2 | 101,397 | Direct | |
| Mar 26, 2026 | Class A Common Stock | SSaleDisposed | −9,883 | $65.21F7 | −$644,470.43 | 91,514 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | Class A Common Stock | MOption exerciseDisposed | −80,000 | $0.00 | $0 | 160,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.93 to $61.91 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 4 through 7 of this Form 4.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.93 to $62.91 per share, inclusive.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.96 to $63.955 per share, inclusive.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.99 to $64.96 per share, inclusive.
Referenced by the price of 1 transaction in Table I.
- F7
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.61 per share, inclusive.
Referenced by the price of 1 transaction in Table I.